Myriad Genetics, Inc. (MYGN) on Tuesday reported first-quarter results with revenue rising slightly from last year, while losses widened compared to the prior period.
The company posted revenue of $200.4 million for the three months ended March 31, 2026, up from $195.9 million a year earlier. Net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter. Loss per share was $0.36 for the quarter, while weighted average shares outstanding stood at 93.7 million.
Operating loss came in at $30.7 million, up from $29.0 million last year, as total operating expenses increased to $168.3 million from $163.2 million. The higher expenses were driven in part by research and development costs of $27.1 million and sales and marketing expenses of $73.6 million.
MYGN is currently trading after hours at $4.47, down $0.56 or 11.13 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.